These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Mechanisms of the anti-inflammatory and antifibrotic activity of a sympatholytic agent during toxic pulmonary fibrosis. Skurikhin EG; Khmelevskaya ES; Pershina OV; Andreeva TV; Ermolaeva LA; Krupin VA; Ermakova NN; Reztsova AM; Stepanova IE; Dygai AM Bull Exp Biol Med; 2012 Sep; 153(5):638-43. PubMed ID: 23113245 [TBL] [Abstract][Full Text] [Related]
12. Aerosolized Liposomal Formulation Prevents Enhanced Drug Transfer from Fibrotic Lungs to the Systemic Circulation. Togami K; Kurasho K; Kanehira Y; Tada H; Chono S Curr Drug Deliv; 2021; 18(7):947-954. PubMed ID: 33372874 [TBL] [Abstract][Full Text] [Related]
13. Heterogenous Intrapulmonary Distribution of Aerosolized Model Compounds in Mice with Bleomycin-Induced Pulmonary Fibrosis. Togami K; Kanehira Y; Yumita Y; Ozaki H; Wang R; Tada H; Chono S J Aerosol Med Pulm Drug Deliv; 2023 Dec; 36(6):289-299. PubMed ID: 37843890 [No Abstract] [Full Text] [Related]
15. Effect of spiperone on mesenchymal multipotent stromal and hemopoietic stem cells under conditions of pulmonary fibrosis. Skurikhin EG; Khmelevskaya ES; Ermakova NN; Pershina OV; Reztsova AM; Krupin VA; Stepanova IE; Reztsova VM; Reikhart DV; Dygai AM Bull Exp Biol Med; 2014 May; 157(1):132-7. PubMed ID: 24913578 [TBL] [Abstract][Full Text] [Related]
16. Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model. Wuyts WA; Willems S; Vos R; Vanaudenaerde BM; De Vleeschauwer SI; Rinaldi M; Vanhooren HM; Geudens N; Verleden SE; Demedts MG; Thomeer M; Verbeken EK; Verleden GM Exp Lung Res; 2010 Dec; 36(10):602-14. PubMed ID: 20874225 [TBL] [Abstract][Full Text] [Related]
17. Improvement of the pharmacokinetics and antifibrotic effects of nintedanib by intrapulmonary administration of a nintedanib-hydroxypropyl-γ-cyclodextrin inclusion complex in mice with bleomycin-induced pulmonary fibrosis. Togami K; Ogasawara A; Irie S; Iwata K; Yamaguchi K; Tada H; Chono S Eur J Pharm Biopharm; 2022 Mar; 172():203-212. PubMed ID: 35183716 [TBL] [Abstract][Full Text] [Related]
18. Amelioration of bleomycin-induced pulmonary fibrosis in a mouse model by a combination therapy of bosentan and imatinib. Chilakapati SR; Serasanambati M; Vissavajjhala P; Kanala JR; Chilakapati DR Exp Lung Res; 2015 May; 41(4):173-88. PubMed ID: 25844688 [TBL] [Abstract][Full Text] [Related]
19. Alteration in Intrapulmonary Pharmacokinetics of Aerosolized Model Compounds Due to Disruption of the Alveolar Epithelial Barriers Following Bleomycin-Induced Pulmonary Fibrosis in Rats. Togami K; Chono S; Tada H J Pharm Sci; 2016 Mar; 105(3):1327-34. PubMed ID: 26886341 [TBL] [Abstract][Full Text] [Related]
20. M2 macrophages induce EMT through the TGF-β/Smad2 signaling pathway. Zhu L; Fu X; Chen X; Han X; Dong P Cell Biol Int; 2017 Sep; 41(9):960-968. PubMed ID: 28493530 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]